Loading...
•
Jun 30
Akebia Q2 2025 Earnings Report
Estimated Revenue:$47.6M
-5.5% YoY
Estimated EPS:-$0.03
+38.5% YoY
Key Takeaways
Akebia Therapeutics delivered a strong performance in Q2 2025, achieving a net income of $0.2 million, a substantial improvement from a net loss in the prior year. This turnaround was primarily fueled by a significant increase in total revenues to $62.5 million, largely due to the continued growth of Vafseo and increased Auryxia sales.
Total revenues increased to $62.5 million in Q2 2025, up from $43.6 million in Q2 2024, driven by Vafseo's U.S. launch and increased Auryxia sales.
Vafseo net product revenue reached $13.3 million in Q2 2025, with prescription demand growing approximately 55% over Q1 2025.
Akebia achieved a net income of $0.2 million in Q2 2025, a significant improvement compared to a net loss of $8.6 million in Q2 2024.
Cash and cash equivalents stood at $137.3 million as of June 30, 2025, positioning the company to achieve profitability.
Akebia
Akebia
Akebia Revenue by Segment
Revenue by Segment
Vafseo Net Product Revenue
CapyFin.comAuryxia Net Product Revenue
CapyFin.comLicense, Collaboration & Other Revenue
CapyFin.com Forward Guidance
Akebia Therapeutics anticipates continued growth for Vafseo through expanded patient access and operationalized protocols at major dialysis organizations, aiming for broad prescribing access by year-end. The company is also advancing its clinical development programs for Vafseo and believes it is financed to achieve profitability.
Positive Outlook
- DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot, potentially leading to broad prescribing before year-end.
- By September, Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC) are expected to have operationalized protocols to simplify and expand Vafseo prescribing.
- By the end of Q3, dialysis organizations are expected to enable Vafseo prescribing access to more than 75,000 patients, up from 40,000 at the end of Q2.
- Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo, with top-line data expected in early 2027.
- Akebia is working towards initiating VALOR, a Phase 3 clinical trial for vadadustat in late-stage CKD patients not on dialysis, by the end of this year.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company did not provide specific revenue or earnings guidance for future periods.
- The potential impact of generic entrants for Auryxia, despite no current approvals, remains a competitive risk.
- Clinical trial outcomes for VOICE, VOCAL, and VALOR are subject to inherent risks and uncertainties.
- Achieving profitability is based on the current operating plan, which is subject to various market and operational risks.
Loading...
Key Statistics
Market Cap
$833M
P/E Ratio
-14.40
Sector
Health Technology
Industry
Pharmaceuticals Major
52-Week High
$3.99
52-Week Low
$1.24
Vafseo Prescribers
725
Prescriptions per Prescriber
13
Vafseo Refill Rate
80%